X
10Jul

FDA Guidance for Industry for Babesia

0 Comments | | Return |

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.

Check out the Communication page for the complete details on the updated forms or by clicking the link: Communications

Related

CTS Implements HLA Class I and II Testing on the Gemini

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...

Read More >

CTS Charlotte Implements New Laboratory Information System

On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...

Read More >

Reminder-CTS Testing Algorithm to be Revised on December 17, 2018

The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...

Read More >

Spotlight on CTS AABB Annual Meeting Abstract Posters

CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2019

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >

Discontinue HIV-1 IFA Confirmatory Test

CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...

Read More >

Subscribe here to receive CTS updates!

Name